Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.

1. Product Recall
2. Clinical Study
3. Blinding or Masking
4. Pharmacovigilance System
5. Monitoring Plan
6. Council for International Organizations of Medical Sciences
7. Clinical Study Number
8. Marketing Authorization Holder
9. Business Partner
10. Special Situations
11. World Health Organization
12. Risk-Benefit Balance
13. Qualified Person for Pharmacovigilance
14. Corrective and Preventive Action (CAPA)
15. Clinical Trial Application
16. Institutional Review Board
17. Pharmacovigilance
18. Spontaneous (Unsolicited) report
19. Other Safety Issue
20. Adverse Event Report Number
21. Side effect
22. Protocol
23. Signal Detection Plan
24. Non-validated signal
25. New Drug Application
26. Risk Management
27. Signal Prioritization
28. Drug Adverse Event Reporting System
29. Chief Safety Officer
30. Investigational Medicinal Product
31. Drug Product
32. Patient Safety
33. Signal Assessment
34. Risk Communication
35. Clinical Trial
36. Non-serious AESI
37. Regulatory authority
38. Global Safety Database
39. Off-label use
40. Pharmacovigilance
41. Safety Data Exchange Agreement
42. Sponsor
43. Company Safety Committee
44. Medical Review
45. Local Safety Representative
46. Global Patient Safety
47. Affiliate
48. Tolerability
49. Product Quality Complaint
50. Occupational exposure
51. Adverse Event of Special Interest (AESI)
52. Periodic Benefit-Risk Evaluation Report
53. GVP Module I
54. Safety Management Team
55. Solicited reports
56. Adverse Event (AE)
57. Safety Information
58. Labeled or unlabeled
59. background rates
60. Investigator’s Brochure
61. Company Core Data Sheet
62. Informed Consent
63. Health Authority
64. Aggregate Safety Report (ASR)
65. Drug Substance
66. Contract Research Organization (CRO)
67. periodic safety update report (PSUR)
68. Safety Signal
69. Dear Investigator Letter
70. Development Safety Update Report
71. Investigator
72. Product
73. Quality Management System (QMS)
74. Development International Birth Date
75. Reference Safety Information
76. Data Lock Point
77. Organized Data Collection Program
78. Pharmacoepidemiology
79. Risk Management Plan
80. Literature Report
81. Unexpected Events
82. Clinical Development Program
83. Drug Abuse
84. Expectedness
85. Suspected Unexpected Serious Adverse Reaction (SUSAR)
86. Interventional Study
87. Individual Case Safety Report (ICSR)
88. Company Core Safety Information
89. Subject Matter Expert
90. Listedness/ expectedness
91. Signal Validation
92. Signal Detection
93. Serious Adverse Event
94. Safety Assessment Team
95. Post-Marketing Surveillance
96. Causality Assessment
97. Individual Case Safety Report
98. International Conference on Harmonization (ICH)
99. process excellence
100. Product Safety Strategy
101. Adverse Drug Reaction (ADR)
102. EudraVigilance
103. Benefit-risk analysis
104. Signal Management Process
105. Good Clinical Practice
106. BeiGene Representative
107. Investigational New Drug Application
108. National Medical Product Administration
109. Quality Assurance
110. Medical Dictionary for Regulatory Activities (MedRA)
111. Medicines and Healthcare Regulatory Agency
112. Overdose
113. alliance management
114. Periodic Safety Update Report
115. Identified Risk
116. Developmental Risk Management Plan
117. Good Pharmacovigilance Practice
118. Validated Signal
119. Pharmacovigilance System Master File
120. PV Agreement
121. Business Continuity Plan
122. Healthcare Professional
123. Observational study
124. Post-authorization Safety Study
125. Important Potential Risks
126. Urgent Safety Measure
127. Comparator Product
128. Country Safety Lead/Manager
129. Non-Interventional Study
130. Refuted Signal